How Does Quanterix Company Work?

The heart of the Quanterix company's operations lies in its Simoa technology. This digital ELISA platform enables the detection and quantification of individual protein molecules, offering sensitivity several log-folds greater than traditional immunoassays. This breakthrough in Quanterix technology is crucial for identifying low-abundance biomarkers.

Quanterix provides a range of instruments, including the HD-X, SR-X, and SP-X systems, alongside a broad selection of Simoa assay kits. Additionally, the company offers contract research services through its Accelerator Laboratory, supporting over 2,200 projects for 480 customers.

The Quanterix platform serves diverse customer segments in research and clinical diagnostics, with a strong focus on neurology, oncology, inflammation, infectious diseases, and cardiology. These applications support both drug development and the pursuit of new Quanterix diagnostics.

To bolster its supply chain and capabilities, Quanterix acquired EMISSION Inc. in late 2024. This vertical integration aims to secure essential components for next-generation platforms and foster development in a new multi-plex segment for third-party OEM customers.

In December 2024, Quanterix secured proprietary bead technology through the acquisition of EMISSION Inc., expected to close in January 2025. Further strengthening its market position, Quanterix amended its merger agreement with Akoya Biosciences, anticipating an 84% shareholder ownership post-closing in June 2025. This integration aims to create a unified platform for ultra-sensitive protein biomarker detection.

Responding to market challenges, including reduced academic funding, Quanterix initiated cost-saving measures targeting approximately $30 million in annual savings to achieve positive cash flow by 2026. The company launched 12 neurology assays in 2024 and introduced novel p-Tau 205 and p-Tau 212 assays in July 2025 to advance Alzheimer's research.

A significant 2025 initiative is the introduction of Simoa ONE assay kits, designed for compatibility with over 20,000 existing flow cytometers globally. This strategy aims to broaden market access by minimizing the need for new capital equipment purchases, thereby expanding the use of Quanterix diagnostics.

Quanterix's competitive edge is built on the unparalleled sensitivity of its Simoa technology, enabling the detection of biomarkers at previously unattainable concentrations. This technological leadership, supported by a robust intellectual property portfolio and strong brand equity, is further enhanced by strategic partnerships, such as with ARUP Laboratories for Alzheimer's blood tests.

Quanterix holds a leading position in ultra-sensitive biomarker detection, primarily due to its proprietary Simoa technology. The company's strategic acquisition of Akoya Biosciences in 2025 is expected to expand its served addressable market from $1 billion to $5 billion, creating an integrated platform for both blood- and tissue-based protein biomarker analysis.

Quanterix operates in a competitive landscape, facing established companies such as Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific, Qiagen, and Illumina. These companies also offer solutions in diagnostics and life sciences, presenting a dynamic market environment.

The company faces several risks, including the impact of U.S. government policies such as reduced federal research funding and increased tariffs. Challenges also include realizing synergies from recent acquisitions and cost reduction efforts, maintaining internal controls, and achieving market acceptance for new products like the next-generation Simoa ONE instrument.

The financial performance in Q2 2025 indicated operational pressures, with a 29% revenue decline and a widened net loss. This highlights the immediate challenges the Quanterix company is navigating in the current market conditions.